In the 2026 clinical landscape, it isn’t that doctors “dislike” Diclofenac gel—in fact, many prescribe it as a first-line treatment for localized arthritis. However, there are technical frustrations and clinical risks that make doctors cautious.

As a pharmacist, I can break down the professional hesitation into four technical categories:

1. The “Black Box” Warning Conflict

Even though it is a topical gel, the FDA and other global regulators (like the EMA) require it to carry the same Black Box Warning as oral Diclofenac.

• Cardiovascular & GI Risk: Doctors are wary because the label warns of heart attacks, strokes, and stomach bleeding.

   

• The Technical Paradox: While systemic absorption is low ($~6\%$), the regulatory requirement forces doctors to treat it with the same caution as a pill, even if the actual risk is significantly lower.

2. High Rate of Patient Misuse

Doctors often find that patients treat topical gels as “harmless” compared to pills, leading to dangerous application habits:

• Over-Application: Patients often apply it to too many joints at once. The 32g daily limit is a hard technical ceiling; exceeding it can lead to kidney strain ($nephrotoxicity$).

• Broken Skin Application: Patients apply it to cuts or rashes, which “unclocks” the skin barrier and allows $100\%$ absorption, effectively turning a localized gel into a systemic dose.

• Sun Sensitivity: Diclofenac is highly photosensitive. Doctors dislike having to manage chemical burns or “photo-allergic” rashes when patients forget to cover the treated joint in the sun.

3. Efficacy vs. Expectation Gap

• Onset of Action: Unlike an oral painkiller that works in 30 minutes, Diclofenac gel takes up to 7 days of consistent use to build up therapeutic levels in the synovial fluid.

   

• The “Frustrated Patient” Factor: Doctors often “dislike” prescribing it because patients call back after two days claiming it “doesn’t work,” leading to poor treatment compliance.

4. Technical Comparison: Topical vs. Oral Diclofenac